5 Biotech Stocks to Buy for Blockbuster Potential

Biotechnology has boomed over the past few decades as our understanding of living organisms and the human machine has swelled.

Portrait of young scientist looking in microscope while working on medical research in science laboratory.
(Image credit: Getty Images)

Biotechnology has boomed over the past few decades as our understanding of living organisms and the human machine has swelled. As a result, biotech stocks have become some of the most exciting growth plays on Wall Street.

And their potential to deliver sky-high returns is especially explosive when they’re developing a drug with blockbuster potential.

Blockbuster drugs are those popular treatments that generate annual sales of at least $1 billion. They’re uncommon: A drug must have the right combination of price and number of potential patients, so only a handful of treatments at any given time even have the potential to become billion-dollar products. And not all of them live up to their potential.

So how can you pinpoint biotech stocks with these kind of superstar drugs in the pipeline? We suggest turning to Wall Street’s pros.

Here are five promising biotech stocks to buy for their blockbuster-drug potential. TipRanks data (opens in new tab) shows that all five stocks boast a “Strong Buy” consensus among the Wall Street analysts covering them, based on ratings given during the past three months.

Data is as of July 24.

Harriet Lefton
Contributing Writer, Kiplinger.com
Harriet Lefton, originally from the U.K., began her career as a journalist specializing in the niche world of metal markets. She graduated from the University of Cambridge before becoming a qualified U.K. lawyer. Now she has turned her attention to the world of financial blogging, covering U.S. stocks, analysts and all manner of things finance-related.